APA (7th ed.) Citation

Mayer, E., Abramson, V., Jankowitz, R., Falkson, C., Marcom, P., Traina, T., . . . Wolff, A. (2020). TBCRC 030: A phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology, 31(11), 1518. https://doi.org/10.1016/j.annonc.2020.08.2064

Chicago Style (17th ed.) Citation

Mayer, E.L, et al. "TBCRC 030: A Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Triple-negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker." Annals of Oncology 31, no. 11 (2020): 1518. https://doi.org/10.1016/j.annonc.2020.08.2064.

MLA (9th ed.) Citation

Mayer, E.L, et al. "TBCRC 030: A Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Triple-negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker." Annals of Oncology, vol. 31, no. 11, 2020, p. 1518, https://doi.org/10.1016/j.annonc.2020.08.2064.